S
Sarah Zohar
Researcher at University of Paris
Publications - 123
Citations - 3558
Sarah Zohar is an academic researcher from University of Paris. The author has contributed to research in topics: Clinical trial & Population. The author has an hindex of 31, co-authored 117 publications receiving 2954 citations. Previous affiliations of Sarah Zohar include French Institute for Research in Computer Science and Automation & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Dose‐finding approach for dose escalation with overdose control considering incomplete observations
TL;DR: This study shows that the trial duration can be greatly decreased with the TITE‐EWOC, without impacting the proportion of overdosed patients or the number of dose‐limiting toxicities by trial, for all explored dose–toxicity relationships, except for very short inter‐patient arrival times.
Journal ArticleDOI
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization
TL;DR: A Bayesian phase I/II dose-finding design to find the optimal dose is developed, which employs a logistic model with a plateau parameter to capture the increasing-then-plateau feature of the dose–efficacy relationship.
Journal ArticleDOI
Competing designs for drug combination in phase I dose‐finding clinical trials
TL;DR: Using single‐agent dose‐finding methods for combination therapies is not appropriate because it is unreasonable to assume the same dose–toxicity relationship for the combination as for the simple addition of each single agent.
Journal ArticleDOI
Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.
Moreno Ursino,Sarah Zohar,Frederike Lentz,Corinne Alberti,Tim Friede,Nigel Stallard,Emmanuelle Comets,Emmanuelle Comets +7 more
TL;DR: Using PK information in the dose allocation process enriches the knowledge of the dose‐toxicity relationship, facilitating better dose recommendation for subsequent trials and improving the efficiency of dose‐finding trials.
Journal ArticleDOI
Recent developments in adaptive designs for Phase I/II dose-finding studies.
Sarah Zohar,Sylvie Chevret +1 more
TL;DR: The aim of this paper is to present three main approaches proposed to estimate the maximum tolerated dose of a new treatment or combination, in the setting of Phase I/II trials.